Scenario 1: Private Insurance with Manufacturer Program Profile: 45-year-old with employer-provided insurance (Sun Life), BMI 35, type 2 diabetes Coverage: Insurance approves after prior authorization, covers 70% after $500 deductible Calculation: Annual retail cost: $21,000 Deductible: $500 Insurance pays 70% of remaining $20,500 = $14,350 Patient owes: $6,650 Manufacturer program saves: $2,800 Final patient cost: $3,850 annually ($320/month) Verdict: Most affordable scenario
avoid very rich or greasy foods during dose increases
Detailed Phase 3 results from the TRIUMPH-1 program showed the once-weekly GIP, GLP-1 and glucagon agonist cut moderate-to-severe obstructive sleep apnea severity by up to 60.6% and knee osteoarthritis pain by up to 73.1%
33K Views 20 Posts $Eli Lilly and Co (LLY.US)$ reports first-quarter 2026 earnings on April 30, and this print will be less about whether demand for GLP-1 drugs is strong
it can affect your health, energy, and overall well-being
The company called the HIMS product an unapproved, inauthentic, and untested knockoff and announced it would take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework. This was not merely rhetorical